AB0421 Real-world effectiveness of Upadacitinib in patients with rheumatoid arthritis

De Cock, Diederik;Durez, Patrick;Lenaerts, Jan;Westhovens, René;Verschueren, Patrick
(2023) EULAR 2023 European Congress of Rheumatology — Location: (Italy) Milano (31.May.2023)

Files

2023_EULAR_AB0421.pdf
  • Open Access
  • Adobe PDF
  • 304.88 KB
Download

Details

Authors
  • De Cock, Diederik
    Author
  • Durez, PatrickUCLouvain
    Author
  • Lenaerts, Jan
    Author
  • Westhovens, René
    Author
  • Verschueren, Patrick
    Author
Abstract
BACKGROUND: The Janus Kinase (JAK) inhibitor Upadacitinib (UPA) has shown efficacy in rheumatoid arthritis (RA) in trials, yet real-world evidence is lacking. OBJECTIVES: We aimed to assess short-term effectiveness of UPA for standard of care for RA. […]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

De Cock, D., Durez, P., Lenaerts, J., Westhovens, R., & Verschueren, P. (2023). AB0421 Real-world effectiveness of Upadacitinib in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 82(Suppl 1), 1398-1399. https://doi.org/10.1136/annrheumdis-2023-eular.1326 (Original work published 2023)